ClinicalTrials.gg
CompletedNCT00065156Updated Nov 19, 2019Results posted

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

A Phase 2 interventional study of lenalidomide in Myelodysplastic Syndromes, sponsored by Celgene. Completed at 32 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 44 studies testing lenalidomide in Myelodysplastic Syndromes — none open to participants now, none under way, none of them phase 3. Lenalidomide · Myelodysplastic Syndromes.

Enrollment
5th of 43
148 · median 32
Started
2003
with 1 other
Phase 2
24 of 44
none open now
Registered
3rd of 44
by date
Lead sponsor
4 of 44
Celgene

Among the 44 studies testing lenalidomide in Myelodysplastic Syndromes, this one is the 5th largest by enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2003, is one of 24 in phase 2, and was the 3rd registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 323 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 44 studies testing lenalidomide in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing lenalidomide in Myelodysplastic Syndromes as a file.
02

Study summary

This study is a multicenter, single-arm, open-label study of oral lenalidomide monotherapy administered to red blood cell (RBC) transfusion-dependent subjects with low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del (5q31-33) cytogenetic abnormality. Screening procedures will take place within 28 days of the first day of lenalidomide treatment. Subjects will receive lenalidomide in 28-day cycles for up to 6 cycles, or until bone marrow disease progression or progression/relapse following erythroid hematologic improvement is documented. Study visits will occur every cycle (every 28 days) and laboratory monitoring to assess hematological parameters will occur every 14 days. Safety and efficacy assessments to be performed during the study are outlined in the Schedule of Study Assessments.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • MDS
  • CC-5013
  • Revlimid
  • Celgene
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must understand and voluntarily sign an form
  • Age 18 years or older at the time of signing the informed consent
  • Must be able to adhere to the study visit schedule and other protocol requirements.
  • Diagnosis of low or intermediate-1-risk International Prognostic Scoring System (IPSS) Myelodysplastic Syndromes (MDS) without an abnormality of chromosome 5 involving a deletion between bands q31 and q33.
  • Red blood cell (RBC) transfusion-dependent anemia defined as having received greater than or equal to 2 units of RBCs within 8 weeks of the first day of study drug treatment.
  • (ECOG) performance status score of 0, 1 or 2.
  • Women of (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug.
  • Sexually active WCBP must agree to use adequate methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.
  • WCBP must agree to have pregnancy tests every 4 weeks while on study drug.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Prior therapy with lenalidomide.
  • An abnormality of chromosome 5 involving a deletion between bands q31 and q33.
  • Lab Abnormality: (ANC) \<500 cell/mm\^3 (0.5*10\^9/L)
  • Lab Abnormality: count \<50,000/mm\^3 (50*10\^9/L)
  • Lab Abnormality: Serum creatinine >2.5 mg/dL (221 mmol/L)
  • Lab Abnormality: Serum total >2.0 mg/dL (34 mmol/L)
  • Prior greater than or equal to grade 3 National Cancer Institute (NCI) Common Toxicity Criteria (CTC) allergic reaction/ to thalidomide.
  • anemia due to factors such as iron, B12 or folate deficiencies, or hereditary hemolysis or gastrointestinal bleeding
  • If a marrow aspirate is not evaluable for storage iron, transferrin saturation must be > 20% and serum ferritin not less than 50 ng/mL
  • Use of hematopoietic growth factors within 7 days of the first day of study drug treatment.
  • Prior greater than or equal to grade 3 NCI CTC rash or any desquamation (blistering) while taking thalidomide.
  • Chronic use (>2 weeks) of greater than physiologic doses of a agent (dose equivalent to >10 mg/day of prednisone) within 28 days of the first day of study drug treatment.
  • Use of experimental or standard drugs (i.e. chemotherapeutic, , and cytoprotective agents) for the treatment of MDS within 28 days of the first day of study drug treatment.
  • Prior history of other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for greater than or equal to 3 years.
  • Use of any other experimental therapy within 28 days of the first day of study drug treatment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Lenalidomide

    Drug: lenalidomide

Interventions

  • 10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.

    Also known as: CC-5013

06

What researchers measure

Primary outcomes

  1. Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence

    Number of participants who achieved RBC-transfusion independence, which was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (eg, Days 1 to 56, Days 2 to 57, Days 3 to 58, etc), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin.

    Time frame: Up to 2 years

Secondary outcomes

  1. Participants With Adverse Experiences

    Counts of study participants who had adverse events (AEs) during the study. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator. The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.

    Time frame: Up to 2 Years

  2. Participants With a >= 50% Decrease From Baseline in Red Blood Cell (RBC) Transfusion Requirements Over Any Consecutive 56 Days During Study

    A participant was categorized as having a transfusion reduction response if there was a ≥ 50% decrease from pretreatment transfusion requirements (before the start of the study mediation) compared to any consecutive 56 days during the study (i.e. post treatment).

    Time frame: Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years)

  3. Time to Transfusion Independence

    Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Time to transfusion independence was defined as the day of the first dose of study drug to the first day of the first 56-day RBC transfusion-free period.

    Time frame: up to 2 years

  4. Participants Who Relapsed or Maintained Their Transfusion Independence After Achieving Transfusion Independence During the Study

    Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Participants who relapsed required a transfusion after the period of transfusion independence. Participants who maintained transfusion independence did not require a transfusion during the remainder of the study.

    Time frame: up to 2 years

  5. Kaplan Meier Estimate for Duration of Transfusion Independence Response

    Duration of response is measured from the first of the consecutive 56 days during which the participant was free of RBC transfusions to the date of the first RBC transfusion after this period. Duration of response was censored at the date of last visit for participants who maintained transfusion independence.

    Time frame: up to 2 years

  6. Change in Hemoglobin Concentration From Baseline to Maximum Value During Response Period for Responders

    The change from baseline in hemoglobin for participants who became RBC-transfusion independent. The maximum hemoglobin value obtained during the response period is used in the calculation of change from baseline.

    Time frame: Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years)

  7. Participant Counts of Cytogenetic Response

    Participants deemed evaluable by the central cytogenetic review had their cytogenetic response categorized as major or minor. A major cytogenetic response was defined as ≥ 20 metaphases recorded at baseline, and at least 1 post baseline evaluation with ≥ 20 metaphases analyzed with no abnormal metaphases observed. A minor cytogenetic response was defined as ≥ 20 metaphases analyzed at baseline, and at least 1 post baseline evaluation with ≥ 20 metaphases analyzed with a ≥ 50% reduction in the proportion of hematopoietic cells with cytogenetic abnormalities compared with baseline.

    Time frame: up to 2 years

  8. Participant Counts of Platelet Response

    Major platelet response: participants with a minimum pretreatment platelet of \<100,000/mm\^3 in all values within 56 days of start of treatment, an absolute increase of ≥30,000/mm\^3 sustained for ≥56 consecutive days. In platelet transfusion-dependent participants, a major response was stabilization of platelet counts and platelet transfusion independence. Minor platelet response: participants with a minimum pretreatment platelet of \<100,000/mm\^3, a ≥ 50% increase in platelet count with a net increase \>10,000/mm\^3 for a consecutive 56-day period in the absence of platelet transfusions.

    Time frame: up to 2 years

  9. Participant Counts of Absolute Neutrophil Count (ANC) Response

    Major neutrophil response: participants with a minimum pretreatment ANC concentration of \< 1500/mm\^3 in all values obtained within 56 days of start of treatment, a ≥ 100% increase or an absolute increase of ≥ 500/mm\^3, whichever was greater (at least to be ≥ 500/mm\^3), sustained for 56 consecutive days. Minor neutrophil response: participants with a minimum pretreatment ANC concentration of \< 1500/mm\^3, an increase in ANC concentration of ≥ 100% sustained for 56 consecutive days.

    Time frame: up to 2 years

  10. Participants With Complete or Partial Bone Marrow Improvement

    Bone marrow aspirates were assessed by a central reviewer. A complete bone marrow improvement required a baseline French-American-British (FAB) classification (see Baseline Characteristics) of refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB) or chronic myelomonocytic leukemia (CMML) and a during study assessment of no MDS. A partial bone marrow improvement reflected an improved FAB classification compared to baseline (e.g. RARS to RA) but evidence of MDS continued to exist.

    Time frame: up to 2 years

  11. Participants With Bone Marrow Progression

    Bone marrow aspirate was assessed by a central reviewer. Progression is represented in two categories according to changes from baseline in French-American-British (FAB) classification (see Baseline Characteristics): * Baseline classification of refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) to a during treatment (plus 30 days) classification of refractory anemia with excess blasts (RAEB). * Any baseline FAB classification to a during treatment (plus 30 days) classification of acute myeloid leukemia (AML).

    Time frame: up to 2 years

07

Results

Posted Jun 9, 2010

Participant flow

Participant flow — Overall Study
MilestoneLenalidomide
Started148
Modified intent to treat population94
Completed24
Not completed124
Withdrew: Adverse event37
Withdrew: Lack of efficacy52
Withdrew: Withdrawal by subject8
Withdrew: Lost to follow-up1
Withdrew: Death11
Withdrew: Study closed by sponsor2
Withdrew: Disease progression7
Withdrew: Investigator decision2
Withdrew: Non-compliance2
Withdrew: Loss of response1
Withdrew: Secondary malign disease1

Outcome measures

PrimaryParticipants Who Achieved Red Blood Cell (RBC) -Transfusion Independence

Number of participants who achieved RBC-transfusion independence, which was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (eg, Days 1 to 56, Days 2 to 57, Days 3 to 58, etc), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin.

Time frame:
Up to 2 years
Reported as:
Number · participants
Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence
participantsLenalidomide
Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence59
SecondaryParticipants With Adverse Experiences

Counts of study participants who had adverse events (AEs) during the study. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator. The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.

Time frame:
Up to 2 Years
Reported as:
Number · participants
Participants With Adverse Experiences
participantsLenalidomide
At least one AE148
At least one AE related to study drug143
At least one NCI CTC grade 3-4 AE140
At least one NCI CTC grade 3-4 AE related to drug131
At least one serious AE89
At least one serious AE related to study drug40
AE leading to dose reduction or interruption131
AE leading to discontinuation of study drug47
SecondaryParticipants With a >= 50% Decrease From Baseline in Red Blood Cell (RBC) Transfusion Requirements Over Any Consecutive 56 Days During Study

A participant was categorized as having a transfusion reduction response if there was a ≥ 50% decrease from pretreatment transfusion requirements (before the start of the study mediation) compared to any consecutive 56 days during the study (i.e. post treatment).

Time frame:
Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years)
Reported as:
Number · participant
Participants With a >= 50% Decrease From Baseline in Red Blood Cell (RBC) Transfusion Requirements Over Any Consecutive 56 Days During Study
participantLenalidomide
Participants With a >= 50% Decrease From Baseline in Red Blood Cell (RBC) Transfusion Requirements Over Any Consecutive 56 Days During Study70
SecondaryTime to Transfusion Independence

Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Time to transfusion independence was defined as the day of the first dose of study drug to the first day of the first 56-day RBC transfusion-free period.

Time frame:
up to 2 years
Reported as:
Mean · weeks
Time to Transfusion Independence
weeksLenalidomide
Time to Transfusion Independence6.2 ± 6.89
SecondaryParticipants Who Relapsed or Maintained Their Transfusion Independence After Achieving Transfusion Independence During the Study

Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Participants who relapsed required a transfusion after the period of transfusion independence. Participants who maintained transfusion independence did not require a transfusion during the remainder of the study.

Time frame:
up to 2 years
Reported as:
Number · participants
Participants Who Relapsed or Maintained Their Transfusion Independence After Achieving Transfusion Independence During the Study
participantsLenalidomide
Relapsed (had a transfusion after response)35
Maintained transfusion independence24
SecondaryKaplan Meier Estimate for Duration of Transfusion Independence Response

Duration of response is measured from the first of the consecutive 56 days during which the participant was free of RBC transfusions to the date of the first RBC transfusion after this period. Duration of response was censored at the date of last visit for participants who maintained transfusion independence.

Time frame:
up to 2 years
Reported as:
Median · weeks
Kaplan Meier Estimate for Duration of Transfusion Independence Response
weeksLenalidomide
Kaplan Meier Estimate for Duration of Transfusion Independence Response97.0 (52.9 to 191.9)
SecondaryChange in Hemoglobin Concentration From Baseline to Maximum Value During Response Period for Responders

The change from baseline in hemoglobin for participants who became RBC-transfusion independent. The maximum hemoglobin value obtained during the response period is used in the calculation of change from baseline.

Time frame:
Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years)
Reported as:
Mean · g/dL
Change in Hemoglobin Concentration From Baseline to Maximum Value During Response Period for Responders
g/dLLenalidomide
Change in Hemoglobin Concentration From Baseline to Maximum Value During Response Period for Responders6.1 ± 1.92
SecondaryParticipant Counts of Cytogenetic Response

Participants deemed evaluable by the central cytogenetic review had their cytogenetic response categorized as major or minor. A major cytogenetic response was defined as ≥ 20 metaphases recorded at baseline, and at least 1 post baseline evaluation with ≥ 20 metaphases analyzed with no abnormal metaphases observed. A minor cytogenetic response was defined as ≥ 20 metaphases analyzed at baseline, and at least 1 post baseline evaluation with ≥ 20 metaphases analyzed with a ≥ 50% reduction in the proportion of hematopoietic cells with cytogenetic abnormalities compared with baseline.

Time frame:
up to 2 years
Reported as:
Number · participants
Participant Counts of Cytogenetic Response
participantsLenalidomide
Major18
Minor20
None14
SecondaryParticipant Counts of Platelet Response

Major platelet response: participants with a minimum pretreatment platelet of \<100,000/mm\^3 in all values within 56 days of start of treatment, an absolute increase of ≥30,000/mm\^3 sustained for ≥56 consecutive days. In platelet transfusion-dependent participants, a major response was stabilization of platelet counts and platelet transfusion independence. Minor platelet response: participants with a minimum pretreatment platelet of \<100,000/mm\^3, a ≥ 50% increase in platelet count with a net increase \>10,000/mm\^3 for a consecutive 56-day period in the absence of platelet transfusions.

Time frame:
up to 2 years
Reported as:
Number · participants
Participant Counts of Platelet Response
participantsLenalidomide
Major2
Minor0
None13
SecondaryParticipant Counts of Absolute Neutrophil Count (ANC) Response

Major neutrophil response: participants with a minimum pretreatment ANC concentration of \< 1500/mm\^3 in all values obtained within 56 days of start of treatment, a ≥ 100% increase or an absolute increase of ≥ 500/mm\^3, whichever was greater (at least to be ≥ 500/mm\^3), sustained for 56 consecutive days. Minor neutrophil response: participants with a minimum pretreatment ANC concentration of \< 1500/mm\^3, an increase in ANC concentration of ≥ 100% sustained for 56 consecutive days.

Time frame:
up to 2 years
Reported as:
Number · participant
Participant Counts of Absolute Neutrophil Count (ANC) Response
participantLenalidomide
Major9
Minor0
None18
SecondaryParticipants With Complete or Partial Bone Marrow Improvement

Bone marrow aspirates were assessed by a central reviewer. A complete bone marrow improvement required a baseline French-American-British (FAB) classification (see Baseline Characteristics) of refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB) or chronic myelomonocytic leukemia (CMML) and a during study assessment of no MDS. A partial bone marrow improvement reflected an improved FAB classification compared to baseline (e.g. RARS to RA) but evidence of MDS continued to exist.

Time frame:
up to 2 years
Reported as:
Number · participants
Participants With Complete or Partial Bone Marrow Improvement
participantsLenalidomide
Complete bone marrow improvement22
Partial bone marrow improvement15
SecondaryParticipants With Bone Marrow Progression

Bone marrow aspirate was assessed by a central reviewer. Progression is represented in two categories according to changes from baseline in French-American-British (FAB) classification (see Baseline Characteristics): * Baseline classification of refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) to a during treatment (plus 30 days) classification of refractory anemia with excess blasts (RAEB). * Any baseline FAB classification to a during treatment (plus 30 days) classification of acute myeloid leukemia (AML).

Time frame:
up to 2 years
Reported as:
Number · participants
Participants With Bone Marrow Progression
participantsLenalidomide
RA/RARS to RAEB11
RA/RARS/RAEB/CMML to AML6

Adverse events

Collected over Up to 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide—89/148 (60.1%)148/148 (100%)
Most frequent serious events
Showing 10 of 128
Most frequent serious events
EventLenalidomide
Pneumonia Not Otherwise Specified (NOS)Infections and infestations15/148
NeutropeniaBlood and lymphatic system disorders10/148
Anaemia NOSBlood and lymphatic system disorders8/148
DehydrationMetabolism and nutrition disorders8/148
Febrile NeutropeniaBlood and lymphatic system disorders8/148
Acute Leukaemia NOSNeoplasms benign, malignant and unspecified (incl cysts and polyps)7/148
Cardiac Failure CongestiveCardiac disorders6/148
Sepsis NOSInfections and infestations6/148
ThrombocytopeniaBlood and lymphatic system disorders6/148
Deep Vein ThrombosisVascular disorders5/148
Most frequent other events
Showing 10 of 79
Most frequent other events
EventLenalidomide
ThrombocytopeniaBlood and lymphatic system disorders93/148
NeutropeniaBlood and lymphatic system disorders91/148
Diarrhoea Not Otherwise Specified (NOS)Gastrointestinal disorders87/148
PruritusSkin and subcutaneous tissue disorders66/148
FatigueGeneral disorders62/148
Rash NOSSkin and subcutaneous tissue disorders54/148
ArthralgiaMusculoskeletal and connective tissue disorders46/148
NasopharyngitisRespiratory, thoracic and mediastinal disorders44/148
NauseaGastrointestinal disorders41/148
Oedema PeripheralGeneral disorders40/148

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lenalidomide
Mean70.0 ± 10.50
Age, Customized
Age, Customized(participants)Lenalidomide
<= 65 years48
>65 years100
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide
Female97
Male51
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lenalidomide
White143
Hispanic3
Asian/Pacific Islander2
Region of Enrollment
Region of Enrollment(participants)Lenalidomide
United States112
Germany36
Duration of Myelodysplastic Syndrome (MDS)
Duration of Myelodysplastic Syndrome (MDS)(years)Lenalidomide
Mean3.4 ± 3.29
Participants with 5q(-) (31-33) Chromosomal Abnormality
Participants with 5q(-) (31-33) Chromosomal Abnormality(participants)Lenalidomide
Number148
International Prognostic Scoring System (IPSS) Score
International Prognostic Scoring System (IPSS) Score(participants)Lenalidomide
Low (0)49
Intermediate-1 (0.5 to 1.0)69
Intermediate-2 (1.5 to 2.0)7
High (>=2.5)2
Missing (unable to assign)21

3 further baseline measures are reported on the registry.

08

Study locations

32 sites
  • Arizona Cancer Center
    Scottsdale, Arizona 85258, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Arizona Cancer Center
    Tucson, Arizona 85724-5024, United States
  • Desert Hematology & Oncology Medical Group
    Rancho Mirage, California 92270, United States
  • Stanford University Medical Center
    Stanford, California 94305-5750, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Cancer & Blood Disease Center
    Lecanto, Florida 34461, United States
  • University of Miami Sylvester Comp Cancer Center
    Miami, Florida 33136, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612-9497, United States
  • Northwest Georgia Oncology - Wellstar Cancer Research
    Marietta, Georgia 30060, United States
  • Rush-Presbyterian- St. Luke's Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637-1470, United States
  • Midwest Cancer Research Group
    Skokie, Illinois 60077, United States
  • Johns Hopkins Oncology Center
    Baltimore, Maryland 21287-8963, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115-6084, United States
  • Wayne State University School of Medicine
    Detroit, Michigan 48201-2097, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-7680, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • New York Hospital-Cornell
    New York, New York 10021-0034, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021-6007, United States
  • Mt. Sinai Medical Center
    New York, New York 10029, United States
  • University of Rochester- James P. Wilmot Cancer Center
    Rochester, New York 14642, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157-1082, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Oregon Health & Science University
    Portland, Oregon 97201, United States
  • Kaiser Permanente Northwest Region
    Portland, Oregon 97227, United States
  • Western Pennsylvania Cancer Institute
    Pittsburgh, Pennsylvania 15224, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109-4417, United States
  • St. Johannes Hospital
    Duisburg, Germany
09

References and documents

Publications

  • Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A, List AF. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008 Dec 20;26(36):5943-9. doi: 10.1200/JCO.2007.15.5770. Epub 2008 Nov 17. PubMed 19018091 ↗
  • Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, Sugrue MM, Bally C, Kelaidi C, Al Ali N, Fenaux P, Gore SD, Komrokji R. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. Oncotarget. 2017 Jun 14;8(47):81926-81935. doi: 10.18632/oncotarget.18477. eCollection 2017 Oct 10. PubMed 29137233 ↗
  • List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct 5;355(14):1456-65. doi: 10.1056/NEJMoa061292. PubMed 17021321 ↗
  • A.F. List, et.al. Results of the MDS-002 and -003 international phase II studies evaluating lenalidomide (CC-5013; Revlimid) in the treatment of transfusion-dependent (TD) patients with myelodysplastic syndrome (MDS). European Hematology Association 10th Conference June 2-5, 2005 Abstract #0772
  • Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellstrom-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Canizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2. PubMed 28651604 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2003 to primary completion in Aug 2008, 62 months.

Results were first posted in Jun 2010, 1 year 10 months after primary completion.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 62 months is above that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2003
First posted
Jul 18, 2003
StartActual
Jun 1, 2003
Primary completionActual
Aug 1, 2008
CompletionActual
Aug 1, 2008
Results first posted
Jun 9, 2010
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00065156
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jul 18, 2003
Start date
Jun 1, 2003
Primary completion
Aug 1, 2008
Completion
Aug 1, 2008
Results posted
Jun 9, 2010
Last update
Nov 19, 2019

Study contacts

Alan F List, MD
principal investigator · H. Lee Moffitt Cancer Center and Research Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion